Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2652-2658

  Cornely, Oliver A ^a,b   Helfgott, David ^c   Langston, Amelia ^d   Heinz, Werner ^e   Vehreschil, Jörg Janne ^a   Vehreschild, Maria J G T ^a   Krishna, Gopal ^f   Ma, Lei ^f   Huyck, Susan ^f   McCarthy, Michael C ^f  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d EMORY UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POSACONAZOLE;

ADULT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS; CHEMOTHERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIARRHEA; DIGESTIVE SYSTEM FUNCTION DISORDER; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HIGH RISK PATIENT; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; OPEN STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STEADY STATE; TREATMENT DURATION;

ADMINISTRATION, ORAL; ADULT; AGED; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; DIET, HIGH-FAT; DIETARY SUPPLEMENTS; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; GASTROINTESTINAL TRACT; HUMANS; IMMUNOCOMPROMISED HOST; INTESTINAL ABSORPTION; MALE; MIDDLE AGED; MYCOSES; RISK; TRIAZOLES;

EID: 84860117262     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05937-11     Document Type: Article

References (19)

1. AbuTarif MA, Krishna G, Statkevich P. 2010. Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Curr. Med. Res. Opin. 26:397-405.
2. Center for Drug Evaluation and Research. 2005. Clinical pharmacology and biopharmaceutics review(s). Application 22-003:1-69. Center for Drug Evaluation and Research, U. S. Food and Drug Administration, Silver Spring, MD.
3. Cornely OA, Ullmann AJ. 2011. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352.
4. Courtney R, Pai S, Laughlin M, Lim J, Batra V. 2003. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob. Agents Chemother. 47:2788-2795. (Pubitemid 37040249)
5. Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. 2003. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br. J. Clin. Pharmacol. 57:218-222.
6. Gubbins PO, et al. 2006. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob. Agents Chemother. 50:1993-1999. (Pubitemid 43807517)
7. Jang SH, Colangelo PM, Gobburu JV. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119.
8. Krishna G, et al. 2009. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob. Agents Chemother. 53:4749-4752.
9. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. 2009. The pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob. Agents Chemother. 53:958-966.
10. Krishna G, et al. 2008. Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. Pharmacotherapy 28:1223-1232.
11. National Cancer Institute. 2006. Common terminology criteria for adverse events v3.0 (CTCAE), p 1-72. National Cancer Institute, Frederick, MD.
12. Pille S, Bohmer D. 1998. Options for artificial nutrition of cancer patients. Strahlenther. Onkol. 174:52-55. (Pubitemid 28506594)
13. Sabatelli F, et al. 2006. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob. Agents Chemother. 50:2009-2015. (Pubitemid 43807519)
14. Sansone-Parsons A, et al. 2006. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob. Agents Chemother. 50:1881-1883.
15. Schering Corp. 2010. Noxafil (posaconazole) oral suspension 40 mg/ml package insert. Schering Corp., Whitehouse Station, NJ.
16. Shen JX, Krishna G, Hayes RN. 2007. A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. J. Pharm. Biomed. Anal. 43:228-236. (Pubitemid 44856187)
17. Ullmann AJ, et al. 2006. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob. Agents Chemother. 50:658-666. (Pubitemid 43190980)
18. Vehreschild MJ, et al. 2011. Clinically defined chemotherapy-associated bowel syndrome predicts severe complications and death in cancer patients. Haematologica 96:1855-1860.
19. Walsh TJ, et al. 2007. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin. Infect. Dis. 44:2-12. (Pubitemid 44968977)